India mulls legal action against US think tank's 'smear' campaign
This article was originally published in Scrip
Even as India's Prime Minister Narendra Modi is set to begin his high profile five-day visit to the US showcasing the country's best side to top global investors, senior government officials were engaged in a major fire-fighting exercise over allegations against the quality of medicines from India.
You may also be interested in...
Indian industry veteran and secretary general of the Indian Pharmaceutical Alliance, Dilip Shah, has died aged 77. Shah, a former commercial director of Pfizer in India, played a pivotal role in ensuring that the Indian generic industry's voice was heard.
Biocon sees some wins for biosimilar adalimumab in the US and signals more opportunities amid the slower than anticipated build-out for Humira rivals. Chinese competition looms for glargine, but the Indian company declares it “will be competitive if these folks launch.”
India’s National Cancer Grid pilots pooled procurement for 40 drugs including trastuzumab, imatinib, and pemetrexed, delivering median savings of over 80%. Experts discuss with Scrip the prospects of scaling the initiative and what it may mean for pharma’s margins and go-to-market strategy.